|Bid||0.0646 x 900|
|Ask||0.0657 x 800|
|Day's Range||0.0622 - 0.0685|
|52 Week Range||0.0610 - 6.0870|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 09, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.75|
Subscribe to Yahoo Finance Plus to view Fair Value for AVTX
Successfully eliminated $35 million debt paving the way for future growth and innovationDivested AVTX-800 series for potential milestone payments of $45 million, fully focusing the pipeline on Avalo’s promising immunology assetsDisclosed improved cash of approximately $10.2 million as of September 30, 2023 WAYNE, Pa. and ROCKVILLE, Md., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced business updates and financial results for the third quarter of 2023.
WAYNE, Pa. and ROCKVILLE, Md., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it has completed the divestiture of its rights, title and interest in, assets relating to AVTX-801 (D-galactose), AVTX-802 (D-mannose) and AVTX-803 (L-fucose) (collectively, the 800 Series) to AUG Therapeutics, LLC (AUG). The Company previously announced it entered into a purchase agreement with AUG to divest the 800 Series on September 12, 2023 (the Purchase Agreement). AUG
NEW YORK, NY / NewsDirect / September 27th, 2023 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks uti...